Athens 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings
ATHENS escrs

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Refractive and visual outcomes of variable spot scanning ablation vs wavefront-optimised in myopic eyes

Poster Details

First Author: A.Meidani GREECE

Co Author(s):    V. Peponis   P. Mitropoulos           

Abstract Details

Purpose:

To compare refractive and visual outcomes of VSS and WFO ablation for myopia correction.

Setting:

Hypervision Laser Centre, Athens, Greece. Ophthalmiatrion Athens Eye Hospital 2nd Specialized Eye Clinic, Athens, Greece.

Methods:

In this retrospective non randomized study two similar myopic groups (18 eyes each) underwent Lasik. The first group was operated by wavefront-guided ablation using the VISX STAR S4/IR platform and the Intralase Fs 60(Abbot Medical Optics, Inc.,Santa Clara, CA). The second group was operated by wavefront-optimised ablation profile using the WaveLight Allegretto EX 500 platform and FS 200 system(Alcon Laboratories Inc., Forth Worth, TX). Manifest refraction, Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity ( CDVA) were measured pre-op, 1 month and 6 months post-op. Safety, efficacy and predictability were estimated.

Results:

Safety indexes were 1.12 and 1.11 respectively. Efficacy index was 1.09 in both groups. Mean UDVA (decimal) at 1 month post –op was 0.98±0.17 and 1.07±0.14 (p=0.105), at six months 1.04±0.17 and 1.07±0.14 (p=0.538) respectively. CDVA at six months was 1.06±0.14 and 1.08±0.11 respectively, (p=0.592). At 6-months 83.3% and 94.45% of the eyes (p=0.23) respectively achieved UDVA 20/20 or better. The 6- month post –op MRSE was -0.01±0.28D for the VVS group and 0.12±0.24D for WFO group (p=0.026). 94.45% eyes of both groups were within ±0.5D of emetropia. No eye lost 1 or more lines of CDVA.

Conclusions:

Both procedures were safe and effective. Refractive and visual outcomes were similar at six months post-op. FINANCIAL DISCLOUSRE: NONE

Back to Poster listing